SYN-AKE: Evidence, Mechanism, Dosing & Legal Status

SYN-AKE is a synthetic tripeptide engineered by Pentapharm Ltd. (Switzerland, now part of dsm-firmenich) to mimic Waglerin-1, a peptide from Temple Viper (Tropidolaemus wagleri) venom, and marketed as a topical 'Botox-in-a-jar' anti-wrinkle active.3 Its popularity in skincare is large; its independent proof is thin. This monograph separates the convincing mechanism from the over-stated marketing.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol, and not a sourcing or buying guide. SYN-AKE is a topical cosmetic ingredient, not an approved drug; concentrations are reported strictly as seen in manufacturer literature and formulation guides — not as recommendations. Consult a qualified clinician before acting on anything here.

What is SYN-AKE and how does it work?

SYN-AKE is the diacetate salt of a tripeptide, beta-Ala-Pro-Dab-NHBn, INCI Dipeptide Diaminobutyroyl Benzylamide Diacetate, also called Tripeptide-3 (CAS 823202-99-9; the diacetate has molecular weight roughly 495.6 g/mol).214 Chemistry databases list it under PubChem CID 71465152.1 The non-standard 2,4-diaminobutyric acid (Dab) residue carries a positive charge that drives binding to the receptor's anionic site, and the benzylamide cap directs selectivity toward the muscle-type receptor; the molecule is a rationally minimized fragment designed to reproduce the key pharmacophore of the 22-residue venom peptide Waglerin-1 without the parent toxin's systemic toxicity.5

The parent toxin Waglerin-1 is a selective antagonist of the adult muscle-type nicotinic acetylcholine receptor, with notably high affinity at the epsilon-subunit interface, blocking neuromuscular transmission.67 SYN-AKE reproduces this in miniature: in vitro it behaves as a reversible, competitive-type antagonist at the muscular nicotinic acetylcholine receptor (mnAChR). By competing with acetylcholine, it keeps the cation channel closed, prevents sodium influx and depolarization, and so reduces muscle-cell contraction.5 This is the muscle-side analogue of Argireline (acetyl hexapeptide-8), which instead inhibits acetylcholine release on the nerve side — the two are often described as complementary 'Botox-mimetic' topicals.17 Unlike botulinum toxin, the block is reversible and partial, so it softens dynamic lines without abolishing expression.3

Reported activity is essentially local and topical; there is no published human pharmacokinetic dataset for cosmetic use — no measured half-life, Cmax, or systemic exposure. As a small, charged, hydrophilic peptide, transdermal penetration to deep facial musculature is biophysically limited, a recognized caveat for all topical 'Botox-like' peptides whose clinical effect is debated as largely surface smoothing rather than true neuromuscular blockade in vivo.10

What is the evidence by indication?

A 2024 peer-reviewed review of anti-aging peptides notes that across this whole 'Botox-alternative' class only a handful of clinical validations exist, effect sizes are modest, low transdermal absorption is the central limitation, and much efficacy data is manufacturer- or model-derived rather than from large independent trials.10 The table below grades SYN-AKE's evidence by indication.

In-vitro mechanism (the strongest data point). On isolated muscle/receptor systems, SYN-AKE inhibits muscle contraction by up to about 80% via mnAChR antagonism — the foundational efficacy claim, but preclinical and not proof of skin efficacy.183 Human data (weak, sponsored). The headline clinical numbers are manufacturer in-vivo data: a 4% SYN-AKE preparation applied twice daily for 28 days produced roughly 21% mean skin smoothing and 15-20% mean wrinkle-depth reduction, with maximum individual values up to about 52%, a smoothing effect measurable in around 80% of volunteers.114 These are open-label, sponsor-run, and not indexed RCTs.

Peer-reviewed human data exist only for multi-ingredient formulas. A 2026 International Journal of Cosmetic Science study evaluated a serum combining acetyl hexapeptide-8, the SYN-AKE peptide, gluconolactone, niacinamide and laminaria extract, reporting significant improvement in static and dynamic wrinkles plus favorable biomarker changes — but because the peptide is one of five actives, its independent contribution cannot be isolated.8 Similarly, an open-label trial of a multi-active topical containing a 'muscle-contraction-inhibiting peptide' (37 women, twice daily, 3 months) showed statistically significant periocular and perioral wrinkle improvement with no adverse events, but does not name or isolate SYN-AKE.9 Independent confirmation of the peptide can be tracked through trial registries such as ClinicalTrials.gov, where no qualifying isolated-peptide RCT was registered at the time of writing.

What concentrations appear in the literature?

Reported strictly as information, not a protocol. SYN-AKE is used topically only, leave-on, to facial skin in serums, creams or gels; no injectable or oral use is validated or intended.4 Finished products commonly contain 1-4% of the as-supplied solution, with 4% the manufacturer-cited optimum that balances efficacy and tolerability and the level used in the 28-day in-vivo data.1110 An important caveat: the active-peptide content of the supplied solution is far lower than the headline percentage, because the raw material is a dilute aqueous solution — so '% SYN-AKE' on a label refers to the supplied solution, not pure peptide. Application is twice daily, with visible smoothing reported from about 28 days of continuous use and effects that are temporary and reversible: lines return as normal muscle activity resumes after discontinuation.3 The peptide is water-soluble and stable in aqueous, pH-appropriate systems and is frequently paired with acetyl hexapeptide-8 for complementary nerve-side and muscle-side action.1417

How safe is SYN-AKE?

As used in finished cosmetics, SYN-AKE is generally well tolerated; the most common issues are mild skin irritation or sensitivity and rare allergic or contact reactions, with patch testing advised for sensitive skin.1213 The clinical studies of multi-active formulations containing it reported no adverse events.9 EWG Skin Deep scores it 1/10 (low hazard), rating cancer, allergy/immunotoxicity, and developmental/reproductive endpoints as low concern.12 The mechanistic concern unique to a neuromuscular antagonist would be unintended systemic effect, but this is not observed in cosmetic use because transdermal penetration to musculature is low and the block is reversible and local; there is no evidence of systemic absorption or toxicity from topical application.10 Raw-material suppliers nonetheless label the neat substance 'for research/in-vitro use, not for human or animal use,' underscoring that safety is established only for the formulated cosmetic — not for ingestion or injection.2 Contraindications are limited to known hypersensitivity and active dermatitis or a compromised barrier at the application site; pregnancy and lactation lack data, so precautionary avoidance of unstudied off-label use is reasonable.

What is the FDA and WADA status in 2026?

In the United States, SYN-AKE is marketed and regulated as a cosmetic ingredient; under the FD&C Act cosmetics require no FDA premarket approval.12 The substance is registered in FDA's Global Substance Registration System (UNII 38H206R00R, CAS 823202-99-9), but registration confers no approval or efficacy endorsement, and there is no OTC monograph and no 503A/503B compounding listing — that pathway is irrelevant to a topical cosmetic active.2 When sold as neat powder or solution it is commonly labeled 'research use only, not for human/animal use,' which keeps the raw substance outside finished-product regulation.2 Aggressive 'Botox-replacement' drug claims on a cosmetic label could in principle trigger drug-misbranding scrutiny.

For athletes the picture is reassuring: SYN-AKE is not listed on the WADA Prohibited List. It is a topical cosmetic peptide with no documented performance-enhancing or systemic hormonal action, unlike the S2 peptide hormones and growth factors that are banned.16 Anti-doping responsibility still rests with the athlete, so a specific finished product should be verified before use.

Bottom line. SYN-AKE is a clever, mechanistically grounded topical cosmetic peptide: a stable, low-toxicity synthetic mimic of a snake-venom nicotinic-receptor antagonist that, in vitro, convincingly blocks muscle contraction, and, in small or manufacturer or multi-ingredient human studies, modestly softens the appearance of dynamic facial wrinkles over about four weeks at 4% — reversibly, without paralysis. What is proven is the receptor mechanism and a benign topical safety profile; what is hyped is the implied equivalence to botulinum toxin. Evidence grade C-B, with no qualifying human RCT of the isolated peptide. It is a reasonable adjunct cosmetic active, not a substitute for procedural treatment, and emphatically not something to use by any route other than as a finished topical product.